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) 
Chloramphenicol is a widely used antibiotic. It is also well known to cause some potentially lethal
complications such as aplastic anemia, acute leukemia and paroxysmal nocturnal haemoglobinuria Al
though development of aplastic anemia is relatively more frequent, evidence in favour of acute
leukemia caused by chloramphenicol is mostly circumstantial. Very rarely, aplastic anemia caused by
chloramphenicol may degenerate into acute leukemia. We describe a case who developed aplastic
anemia following chl oramphenicol treatment. Bone marrow done at that time was severely aplastic
with no evidence of leukemia. Her bone marrow improved completely with resolution of pancytopenia.
Six months later she was again found to have pancytopenia. Bone marrow examination this time con-
firmed her to be suffering from acute mycloid leukemia. This sequential development of aplastic
anemia and acute leukemia carries some interesting pathogenetic implications.
CASE REPORT 
A twenty year old lady was admitted to the Aga Khan University Hospital with complaints of fever and
generalized weakness. Two months back she had developed high grade fever. Her widal test for
salmonella typhi was positive at a titre of 1:320. She was treated with chloramphenicol. Her fever
subsided but two weeks later she developed increasing weakness and pallor. She was taken to a local
clinic, found to be severely pancytopenic and transferredto this hospital. On examination she was found
to be very pale. There was no lymphadenopathy. Liver was slightly enlarged and splenic tip was barely
palpable. Her haemoglobin was 8g/dl, WBC 700/cmm and platelets 84,000/cmm. Bone marrow
examination revealed a hypocellular marrow (Figure 1).
She was found to have F. coli bacteremia and treated with antibiotics. Over the next few days, her
blood counts improved. Repeat bone marrow examination was normal. She was discharged with
haemobglobin of 10.9g/dl, WBC 5100/cmm with sixty percent neutrophils and a normal platelet count.
The patient remained symptom-free for the next six months. She then started having weakness,
anorexia and body aches. She was readmitted to this hospital with fever. Blood examination revealed
haemoglobin 3.8g/dl, WBC 4700/cmm with seventy-five percent blasts and platelet count of
10,000/cmm. Bone marrow aspirate showed hypercellular marrow heavily infiltrated with blasts
(Figure 2).
The blasts were PAS negative, sudan black positive and non-specific esterase positive. She was
categorized as acute myelomonocytic leukemia (M4). She received induction therapy with three days
of daunorubicin and seven days of cytosine-arabinoside. She responded well to this treatment and a
marrow examination done three weeks later confirmed clinical complete remission of acute leukemia.
DISCUSSION 
Chloramphenicol is an important antibiotic that has been widely used for a IonS time. It has been very
effectively used for the treatment of typhoid fever and for several other infectious disorders of
childhood. Its usage apparently is more common in the third world countries. In Pakistan, it is widely
used in intravenous, oral and topical forms. Chloramphenicol is well known to cause some potentially
lethal complications such as aplastic anemia, acute leukemia and paroxysmal nocturnal
hemoglobinuria1-4. It can cause bone marrow suppression by two mechanisms. More commonly, it can
cause a dose dependent, usually reversible, bone marrow suppression that initially affects eryrthroid
cell line and later involves other cellular elements. Less commonly, chloramphenicol can cause an
idiosyncratic, non dose-dependent, usually irreversible, most often fatal, bone marrow suppression5.
The actual risk of developing fatal asplastic anemia after being treated with chloramphenicol is about 1
in 20,000 to 1 in 30,0006. This is 13 times higher incidence than the risk of aplastic anemia in the
general population. It has been suggested that chloramphenicol causes dose-dependent marrow failure
by affecting proliferation and maturation of differentiated cells. It is heralded by increase in serum iron,
decrease in reticulocytes and vacuolization of the normoblasts7. Another explanation is that
chloramphenicol and some of its intestinal metabolites interact with granulocyte-macrophage colony
stimulating factor (GM-CSF) and the cells producing it. GM-CSF is an important factor as it stimulates
the growth and differentiation of human hematopoietic progenitor cells by activating transcription of
specific genes9. This inhibitory effect of chloramphenicol can be reversed by the use of recombinant
human GM-CSF8. In the aplastic anaemia of idiosyncratic type, chloramphenicol affects the cellular
DNA and renders the cells incapable of differentiation, In some cases a genetic predisposition of the
stem cells to this inhibitory effect of chloramphenicol on the nucleic acid synthesisniay exist10. This
effect has been observed even after topical uses of chloramphenicol11. Chloramphenicol has also been
incriminated to cause acute non- lymphoid leukemia. This effect is similar to that of benzene, ionizing
radiation and alkylating agents12-15. The acute leukemia may or may not be preceded byaplastic
anemia16. Marrows cells have shown unusual chromosomal changes including vacuolization and a
large telocentric marker chromosome. Similar changes have been observed in lymphoid cells cultured
in the presence of chloramphenicol17. A population based case-control study carried out in Shanghai
suggested a significant dose response relationship between the drug use and the risk ofacute
leukemias18. Most of this evidence, however, is still circumstantial. Our patient provides a clear
association ofchloramphenicol induced aplastic anemia and subsequent development of acute leukemia.
Initial recovery from aplastic anemia in this case is more suggestive of dose-dependent effect rather
than an idiosyncratic reaction. Chloramphenicol may have caused DNA damage while inducing aplasia,
subsequently degenerating into acute leukemia. However, it is more plausible that patient may have
already sub-clinical acute leukemia at the time of initial presentation and that may have made the stem
cells more susceptible to the inhibitory effect of chloramphenicol. Dose- dependent type of aplasia and
short time interval between aplastic anemia and subsequent acute leukemia are in favour of this
hypothesis. In conclusion we have described a patient who developed chloramphenicol induced aplastic
anemia, who subsequently developed acute leukemia. We hypothesize that sub-clinical leukemia may
have already existed and could have increased the tendency to develop chloramphenicol induced bone
marrow suppression.
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